Daewoong Pharmaceutical’s P-CAB class gastroesophageal reflux disease (GERD) treatment ‘Fexclu’ has received conditional approval from the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee. The committee decided reimbursement was appropriate for the drugs if the company accepts a price below the appraised amount. Accordingly, their reimbursement will be determined in the drug price negotiations with NHIS that will follow.

The NHIS announced that it held the 5th 2022 Drug Reimbursement Evaluation Committee (DREC) meeting on the 12th to deliberate on the adequacy of providing insurance benefits to 4 drugs including Fexclu.

The 4 drugs that were delib